{
    "id": 6427,
    "fullName": "SMO W281C",
    "impact": "missense",
    "proteinEffect": "no effect - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SMO W281C lies within the ligand-binding pocket of the Smo protein (PMID: 25759020). W281C is predicted to have no effect on Smo protein function, as demonstrated by lack of increased basal Hedgehog (Hh) pathway signaling in cell culture, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759020).",
            "references": [
                {
                    "id": 2677,
                    "pubMedId": 25759020,
                    "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759020"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "W281C",
    "createDate": "05/19/2015",
    "updateDate": "09/24/2019",
    "referenceTranscriptCoordinates": {
        "id": 123243,
        "transcript": "NM_005631",
        "gDna": "chr7:g.129205705G>T",
        "cDna": "c.843G>T",
        "protein": "p.W281C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2203,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line expressing SMO W281C was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020).",
            "molecularProfile": {
                "id": 6277,
                "profileName": "SMO W281C"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2677,
                    "pubMedId": 25759020,
                    "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6279,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",
            "molecularProfile": {
                "id": 6277,
                "profileName": "SMO W281C"
            },
            "therapy": {
                "id": 1587,
                "therapyName": "Taladegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5520,
                    "pubMedId": 25759019,
                    "title": "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759019"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6290,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",
            "molecularProfile": {
                "id": 6277,
                "profileName": "SMO W281C"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5520,
                    "pubMedId": 25759019,
                    "title": "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759019"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6297,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",
            "molecularProfile": {
                "id": 6277,
                "profileName": "SMO W281C"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5520,
                    "pubMedId": 25759019,
                    "title": "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759019"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6277,
            "profileName": "SMO W281C",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123243,
            "transcript": "NM_005631",
            "gDna": "chr7:g.129205705G>T",
            "cDna": "c.843G>T",
            "protein": "p.W281C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}